{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:02:51Z","timestamp":1790427771693,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.transproceed.2026.07.032","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:29Z","timestamp":1787169929000},"page":"1424-1428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early First-Line Bortezomib for Acute Antibody-Mediated Rejection: A Retrospective Review of Long-Term Outcomes From a Uniform Single-Center Protocol"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7223-5034","authenticated-orcid":false,"given":"Keren","family":"Tzukert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Benedek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Pizov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Imam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Khalaileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal Dranitzki","family":"Elhalel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2026.07.032_bib0001","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0002","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1111\/ajt.16463","article-title":"Long-term kidney transplant graft survival-Making progress when most needed","volume":"21","author":"Poggio","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0004","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.3390\/jcm12154916","article-title":"Emerging therapies for antibody-mediated rejection in kidney transplantation","volume":"12","author":"Abuazzam","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0006","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0007","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0008","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0009","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The second international consensus guidelines on the management of BK polyomavirus in kidney transplantation","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0010","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1111\/j.1600-6143.2009.02904.x","article-title":"BK virus in solid organ transplant recipients","volume":"9","author":"Hirsch","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0011","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0012","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/nep.12659","article-title":"Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: a single-centre case series","volume":"21","author":"De Sousa-Amorim","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0013","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3349\/ymj.2015.56.6.1638","article-title":"The effect of bortezomib on antibody-mediated rejection after kidney transplantation","volume":"56","author":"Lee","year":"2015","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/jcm9020529","article-title":"The preliminary results of bortezomib used as a primary treatment for an early acute antibody-mediated rejection after kidney transplantation-a single-center case series","volume":"9","author":"Kolonko","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0015","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ndt\/gfaf097","article-title":"Antibody-mediated rejection\u2014treatment standard","volume":"40","author":"B\u00f6hmig","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0016","doi-asserted-by":"crossref","unstructured":"Bhadauria D, Kumar S, Yachha M, Kaul A, Patel MR, Kushwaha RS, et al. Efficacy and safety of bortezomib in the treatment of active antibody-mediated rejection in adult kidney-transplant recipients: a single-center retrospective study. Indian J Transpl 2022;16:101\u20136.","DOI":"10.4103\/ijot.ijot_155_20"},{"key":"10.1016\/j.transproceed.2026.07.032_bib0017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526003878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526003878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:48:41Z","timestamp":1790426921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134526003878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0041134526003878"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.07.032","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early First-Line Bortezomib for Acute Antibody-Mediated Rejection: A Retrospective Review of Long-Term Outcomes From a Uniform Single-Center Protocol","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}